This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
BernsteinJ.A., LangD.M., KhanD.A.The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol.2014; 133(5): 1270–1277.
2.
Sánchez-BorgesM., AseroR., AnsoteguiI.J.; WAO Scientific and Clinical Issues Council. Diagnosis and treatment of urticaria and angioedema: A worldwide perspective. World Allergy Organ J.2012; 5(11): 125–147.
3.
NettisE., ColanardiM.C., ParadisoM.T., FerranniniA.Desloratadine in combination with montelukast in the treatment of chronic urticaria: A randomized, double-blind, placebo-controlled study. Clin Exp Allergy.2004; 34(9): 1401–1407.
4.
Di LorenzoG., PacorM.L., MansuetoP.Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol.2004; 114(3): 619–625.
5.
WanK.S.Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatolog Treat.2009; 20(4): 194–197.
